January 2013
Drug Marketing to Doctors: Changes May Be On the Way
The cornerstone of many FDA enforcement actions against pharmaceuticals manufacturers in recent years has been the charge that they have "misbranded" their pharmaceutical products by promoting them for uses not approved by the FDA. Now, the Second Circuit has thrown the concept of criminal liability for misbranding by means of off-label-use promotion into turmoil.
Log In
Subscribers: Log in below to read the full story
Already subscribe but haven't registered for all the benefits of the website?
Subscribe
Click below to subscribe to
MEDICAL MALPRACTICE LAW & STRATEGY
Pay-Per-View
You can purchase this article for $20.00
Click below
Follow us